| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Ordinary Shares | Options Exercise | +150,000 | +1000% | 165,000 | 04 Mar 2025 | Direct | F1, F2 | ||
| transaction | NAMS | Ordinary Shares | Sale | $3,055,500 | -150,000 | -91% | $20.37 | 15,000 | 04 Mar 2025 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Option (right to buy) | Options Exercise | $0 | -150,000 | -89% | $0.000000 | 18,073 | 04 Mar 2025 | Ordinary Shares | 150,000 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | The exercise price of the option is EUR 1.16392. |
| F2 | The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. |
| F3 | The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |